Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul;84(7):1207-1220.
doi: 10.1016/j.ard.2025.01.050. Epub 2025 Mar 18.

The role of multicriteria decision analysis in the development of candidate classification criteria for antisynthetase syndrome: analysis from the CLASS project

Giovanni Zanframundo  1 Eduardo Dourado  2 Iazsmin Bauer-Ventura  3 Sara Faghihi-Kashani  4 Akira Yoshida  5 Aravinthan Loganathan  6 Daphne Rivero-Gallegos  7 Darosa Lim  8 Francisca Bozán  9 Gianluca Sambataro  10 Sangmee Sharon Bae  11 Yasuhiko Yamano  12 Francesco Bonella  13 Tamera J Corte  14 Tracy Jennifer Doyle  15 David Fiorentino  16 Miguel Angel Gonzalez-Gay  17 Marie Hudson  18 Masataka Kuwana  5 Ingrid E Lundberg  19 Andrew Mammen  20 Neil McHugh  21 Frederick W Miller  22 Carlomaurizio Montecucco  1 Chester V Oddis  23 Jorge Rojas-Serrano  7 Jens Schmidt  24 Albert Selva-O'Callaghan  25 Victoria P Werth  8 Paul Hansen  26 Davide Rozza  27 Carlo A Scirè  28 Garifallia Sakellariou  29 Yuko Kaneko  30 Konstantinos Triantafyllias  31 Santos Castañeda  32 Maria Laura Alberti  33 Martín Gerardo Greco Merino  34 Christopher Fiehn  35 Yair Molad  36 Marcello Govoni  37 Ran Nakashima  38 Erkan Alpsoy  39 Margherita Giannini  40 Hector Chinoy  41 Laure Gallay  42 Esther Ebstein  43 Julien Campagne  44 André Pinto Saraiva  45 Edoardo Conticini  46 Gian Domenico Sebastiani  47 Laura Nuño-Nuño  48 Salvatore Scarpato  49 Elena Schiopu  50 Matthew Parker  14 Massimiliano Limonta  51 CLASS project participating investigatorsLorenzo Cavagna  52 Rohit Aggarwal  23
Affiliations

The role of multicriteria decision analysis in the development of candidate classification criteria for antisynthetase syndrome: analysis from the CLASS project

Giovanni Zanframundo et al. Ann Rheum Dis. 2025 Jul.

Abstract

Objectives: To develop and evaluate the performance of multicriteria decision analysis (MCDA)-driven candidate classification criteria for antisynthetase syndrome (ASSD).

Methods: A list of variables associated with ASSD was developed using a systematic literature review and then refined into an ASSD key domains and variables list by myositis and interstitial lung disease (ILD) experts. This list was used to create preferences surveys in which experts were presented with pairwise comparisons of clinical vignettes and asked to select the case that was more likely to represent ASSD. Experts' answers were analysed using the Potentially All Pairwise RanKings of all possible Alternatives method to determine the weights of the key variables to formulate the MCDA-based classification criteria. Clinical vignettes scored by the experts as consensus cases or controls and real-world data collected in participating centres were used to test the performance of candidate classification criteria using receiver operating characteristic curves and diagnostic accuracy metrics.

Results: Positivity for antisynthetase antibodies had the highest weight for ASSD classification. The highest-ranked clinical manifestation was ILD, followed by myositis, mechanic's hands, joint involvement, inflammatory rashes, Raynaud phenomenon, fever, and pulmonary hypertension. The candidate classification criteria achieved high areas under the curve when applied to the consensus cases and controls and real-world patient data. Sensitivities, specificities, and positive and negative predictive values were >80%.

Conclusions: The MCDA-driven candidate classification criteria were consistent with published ASSD literature and yielded high accuracy and validity.

PubMed Disclaimer

Conflict of interest statement

Competing interests The authors report the following potentially relevant financial activities: GS has received speaking fees from Boehringer Ingelheim. FB has received consulting fees from Boehringer Ingelheim, Sanofi, Bristol Myers Squibb, and Savara Pharma; speaking fees from Boehringer Ingelheim and Sanofi; and support for attending meetings from Boehringer Ingelheim, AstraZeneca, Atyr, and Savara Pharma. TC has received consulting fees from 4D, Avalyn Therapeutics, Boehringer Ingleheim, Bridge Biotherapeutics, Bristol Myers Squibb, Cincera, DevPro, Endeavour BioMedicine, Pharmaxis, Pliant, and Roche; and speaking fees from Boehringer Ingleheim, Bristol Myers Squibb, and Roche. TD has received grants from Bayer, Genentech, and Sanofi. DFF has received consulting fees from Annexon, Argenx, Biogen, Bristol Meyers Squibb, IgM, Kyverna, Nuvig, Octapharma, Paragon, Pfizer, and Priovant. MH has received grants from AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, and Pfizer; and speaking fees from AstraZeneca and Boehringer Ingelheim. MK has received research grants from Boehringer Ingelheim, MBL, and Ono Pharmaceuticals; speaking fees from Asahi Kasei Parma, Boehringer Ingelheim, Chugai, Eisai, Janssen, Kissei, Mochida, Nippon Shinyaku, and Ono Pharmaceuticals; and consulting fees from AstraZeneca, Boehringer Ingelheim, Chugai, GSK, Kissei, and Mochida. IL has received consulting fees from Argenx, Bristol Myers Squibb, Chugai, Corbus Pharmaceutical, EMD Serono Research & Development Institute, Galapagos, and Pfizer; speaking fees from Boehringer Ingelheim; and has stock or stock options from Novartis and Roche. JS has received grants from Kezar; consulting fees from CSL Behring, DSMB, Grifols, Janssen, and Takeda; speaking fees from CSL Behring, Takeda, and UCB; and support for attending meetings from CSL Behring. VW has received grants from Amgen, AstraZeneca, Biogen, Bristol Myers Squibb, Caribou, Corbus Pharmaceuticals, CSL Behring, Gilead, Horizon, Pfizer, Priovant, Regeneron, Rome Pharmaceuticals, Ventus, and Viela; and consulting fees from AbbVie, Alpine Immune Sciences, Amgen, Anaptysbio, Argenx, AstraZeneca, Biogen, Bristol Myers Squibb, Cabaletta Bio, Calyx, Crisalis, CSL Behring, Cugene, EMD Sorona, Evommune, Gilead, GSK, Horizon, Immunovant, Innovaderm, Janssen, Kwoya Kirin, Lilly, Merck, Nektar, Nuvig Pharmaceuticals, Pfizer, Regeneron, Rome Pharmaceuticals, Sanofi, Takeda, UCB, Ventus, Viela Bio, and Xencor. CS has received grants from AbbVie, Galapagos, and Lilly; and consulting fees from AbbVie. GS has received speaking fees from Boehringer Ingelheim. SC has received speaking fees from Eli Lilly, GSK, Novartis, and UCB; support for attending meetings from Eli Lilly, Janssen, and Pfizer; and has received equipment, materials, drugs, medical writing, gifts or other services from Grunenthal and UCB. MLA has received speaking fees from Boehringer Ingelheim and Tecnofarma; and support for attending meetings from Boehringer Ingelheim, Tuteur, and Raffo. MG has received consulting fees from AstraZeneca and UCB; and speaking fees from AbbVie, AstraZeneca, Eli Lilly, and GSK; support for attending meetings from AstraZeneca. RN has received speaking fees from Astellas Pharma, Boehringer Ingelheim, Daiichi Sankyo, Medical & Biological Laboratories, and Mitsubishi Tanabe Pharma Corporation. EA has received speaking fees from AbbVie, Johnson & Johnson, Lilly, and UCB. HC has received grants from Pfizer; and consulting fees from AstraZeneca, Horizon Therapeutics, PTC Therapeutics, and Pfizer; speaking fees from GSK, and UCB. EE has received consulting fees from Bristol Myers Squibb, Galapagos, and Novartis; and support for attending meetings from AbbVie, Novartis, and UCB. APS has received speaking fees from Nordic Pharma; and has stock or stock options from Pfizer. EC has received consulting fees from GSK; and speaking fees from Eli Lilly and GSK. LNN has received support for attending meetings from AbbVie, Nordic Pharma, and Novartis. MP has received speaking fees from Boehringer Ingelheim. LC has received consulting fees from Boehringer Ingelheim; and speaking fees from Alexion, Boehringer Ingelheim, and GSK. RA has received grants from Boehringer Ingelheim, Bristol Myers Squibb, EMD Serono, Janssen, Mallinckrodt, Pfizer, and Q32; and consulting fees from Actigraph, Alexion, ANI Pharmaceuticals, Argenx, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Cabaletta Bio, Capella Bioscience, Corbus, CSL Behring, EMD Serono, Galapagos, Horizon Therapeutics, I-Cell, Janssen, Kezar, Kyverna, Merck, Novartis, Nuvig Therapeutics, Octapharma, Pfizer, Regeneron, Roivant, Sanofi, Teva, Artsome, Capstanx, and Manta. The remaining authors have no conflicts of interest to disclose.

Similar articles

Cited by

Supplementary concepts

LinkOut - more resources